Wednesday, October 7, 2026

Fixed Income & Forex

3 articles

Treasury Yields Near Two-Decade Highs as Bond Selloff Forces Risk Asset Repricing

Treasury Yields Near Two-Decade Highs as Bond Selloff Forces Risk Asset Repricing

A global bond selloff has pushed Treasury yields toward levels not seen in twenty years, as Fed Governor Christopher Waller signals a hawkish pivot driven by Iran War-induced inflation. The FOMC held rates at 3.50–3.75% in a narrow 8-4 vote, but markets are now pricing in hikes. Risk assets, EM currencies, and income strategies built on cheap money face growing pressure.

LM Salvado•
Treasury Yields Near 20-Year Highs as Global Bond Selloff Hits G7 Crisis Threshold

Treasury Yields Near 20-Year Highs as Global Bond Selloff Hits G7 Crisis Threshold

The 30-year Treasury yield is approaching two-decade highs while UK gilt yields have surged past 5.10%, triggering cascading volatility across equities, currencies, and credit markets. G7 finance ministers are convening to coordinate a response, signaling the selloff has escalated beyond normal market turbulence. Persistent inflation fears, Middle East conflict pushing oil higher, and UK fiscal stress are converging into a multi-front pressure event with no clear resolution.

LM Salvado•
UK 10-Year Gilt Yields Hit 5.10% as Sterling Slides on Starmer Political Crisis

UK 10-Year Gilt Yields Hit 5.10% as Sterling Slides on Starmer Political Crisis

UK 10-year gilt yields surged to 5.10% as sterling sold off sharply, driven by a political crisis threatening the Starmer government and a proposed banking surcharge hike from 3% to 5%. Rate-sensitive sectors including housebuilders and banks led equity losses. With futures markets pricing only a 1-in-3 chance of a Federal Reserve cut in 2026, there is no near-term global rate anchor to stabilize UK asset flows.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com